Year |
Citation |
Score |
2020 |
Jurkowski MP, Bettio L, K Woo E, Patten A, Yau SY, Gil-Mohapel J. Beyond the Hippocampus and the SVZ: Adult Neurogenesis Throughout the Brain. Frontiers in Cellular Neuroscience. 14: 576444. PMID 33132848 DOI: 10.3389/fncel.2020.576444 |
0.796 |
|
2020 |
Jurkowski MP, Bettio L, K. Woo E, Patten A, Yau S, Gil-Mohapel J. Beyond the Hippocampus and the SVZ: Adult Neurogenesis Throughout the Brain Frontiers in Cellular Neuroscience. 14. DOI: 10.3389/fncel.2020.576444 |
0.793 |
|
2017 |
Bettio LEB, Gil-Mohapel J, Patten AR, O'Rourke NF, Hanley RP, Gopalakrishnan K, Wulff JE, Christie BR. Effects of Isx-9 and stress on adult hippocampal neurogenesis: Experimental considerations and future perspectives. Neurogenesis (Austin, Tex.). 4: e1317692. PMID 28656155 DOI: 10.1080/23262133.2017.1317692 |
0.797 |
|
2016 |
Brocardo PS, Gil-Mohapel J, Wortman R, Noonan A, McGinnis E, Patten AR, Christie BR. The Effects of Ethanol Exposure During Distinct Periods of Brain Development on Oxidative Stress in the Adult Rat Brain. Alcoholism, Clinical and Experimental Research. PMID 27862017 DOI: 10.1111/acer.13266 |
0.813 |
|
2016 |
Bettio LE, Patten AR, Gil-Mohapel J, O'Rourke NF, Hanley RP, Kennedy S, Gopalakrishnan K, Rodrigues AL, Wulff J, Christie BR. ISX-9 can potentiate cell proliferation and neuronal commitment in the rat dentate gyrus. Neuroscience. PMID 27373772 DOI: 10.1016/J.Neuroscience.2016.06.042 |
0.823 |
|
2016 |
Triviño-Paredes J, Patten AR, Gil-Mohapel J, Christie BR. The Effects of Hormones and Physical Exercise on Hippocampal Structural Plasticity. Frontiers in Neuroendocrinology. PMID 26989000 DOI: 10.1016/J.Yfrne.2016.03.001 |
0.787 |
|
2016 |
Fontaine CJ, Patten AR, Sickmann HM, Helfer JL, Christie BR. Effects of pre-natal alcohol exposure on hippocampal synaptic plasticity: Sex, age and methodological considerations. Neuroscience and Biobehavioral Reviews. PMID 26906760 DOI: 10.1016/J.Neubiorev.2016.02.014 |
0.793 |
|
2016 |
Bettio LE, Neis VB, Pazini FL, Brocardo PS, Patten AR, Gil-Mohapel J, Christie BR, Rodrigues AL. The antidepressant-like effect of chronic guanosine treatment is associated with increased hippocampal neuronal differentiation. The European Journal of Neuroscience. PMID 26779605 DOI: 10.1111/ejn.13172 |
0.785 |
|
2016 |
Patten AR, Sickmann HM, Dyer RA, Innis SM, Christie BR. Corrigendum to "Omega-3 fatty acids can reverse the long-term deficits in hippocampal synaptic plasticity caused by prenatal ethanol exposure" [Neurosci. Lett. 551C (2013) 7-11] Neuroscience Letters. DOI: 10.1016/j.neulet.2016.01.020 |
0.816 |
|
2015 |
Patten AR, Yau SY, Fontaine CJ, Meconi A, Wortman RC, Christie BR. The Benefits of Exercise on Structural and Functional Plasticity in the Rodent Hippocampus of Different Disease Models. Brain Plasticity (Amsterdam, Netherlands). 1: 97-127. PMID 29765836 DOI: 10.3233/BPL-150016 |
0.761 |
|
2015 |
Patten AR, Sawchuk S, Wortman RC, Brocardo PS, Gil-Mohapel J, Christie BR. Prenatal ethanol exposure impairs temporal ordering behaviours in young adult rats. Behavioural Brain Research. PMID 26632335 DOI: 10.1016/J.Bbr.2015.11.032 |
0.805 |
|
2014 |
Patten AR, Fontaine CJ, Christie BR. A comparison of the different animal models of fetal alcohol spectrum disorders and their use in studying complex behaviors. Frontiers in Pediatrics. 2: 93. PMID 25232537 DOI: 10.3389/fped.2014.00093 |
0.818 |
|
2014 |
Gil-Mohapel J, Titterness AK, Patten AR, Taylor S, Ratzlaff A, Ratzlaff T, Helfer J, Christie BR. Prenatal ethanol exposure differentially affects hippocampal neurogenesis in the adolescent and aged brain. Neuroscience. 273: 174-88. PMID 24846617 DOI: 10.1016/J.Neuroscience.2014.05.012 |
0.83 |
|
2014 |
Sickmann HM, Patten AR, Morch K, Sawchuk S, Zhang C, Parton R, Szlavik L, Christie BR. Prenatal ethanol exposure has sex-specific effects on hippocampal long-term potentiation. Hippocampus. 24: 54-64. PMID 23996604 DOI: 10.1002/hipo.22203 |
0.844 |
|
2013 |
Patten AR, Gil-Mohapel J, Wortman RC, Noonan A, Brocardo PS, Christie BR. Effects of Ethanol Exposure during Distinct Periods of Brain Development on Hippocampal Synaptic Plasticity. Brain Sciences. 3: 1076-94. PMID 24961522 DOI: 10.3390/brainsci3031076 |
0.827 |
|
2013 |
Patten AR, Sickmann H, Hryciw BN, Kucharsky T, Parton R, Kernick A, Christie BR. Long-term exercise is needed to enhance synaptic plasticity in the hippocampus. Learning & Memory (Cold Spring Harbor, N.Y.). 20: 642-7. PMID 24131795 DOI: 10.1101/lm.030635.113 |
0.828 |
|
2013 |
Patten AR, Moller DJ, Graham J, Gil-Mohapel J, Christie BR. Liquid diets reduce cell proliferation but not neurogenesis in the adult rat hippocampus. Neuroscience. 254: 173-84. PMID 24060822 DOI: 10.1016/j.neuroscience.2013.09.024 |
0.732 |
|
2013 |
Patten AR, Brocardo PS, Sakiyama C, Wortman RC, Noonan A, Gil-Mohapel J, Christie BR. Impairments in hippocampal synaptic plasticity following prenatal ethanol exposure are dependent on glutathione levels. Hippocampus. 23: 1463-75. PMID 23996467 DOI: 10.1002/hipo.22199 |
0.813 |
|
2013 |
Patten AR, Sickmann HM, Dyer RA, Innis SM, Christie BR. Omega-3 fatty acids can reverse the long-term deficits in hippocampal synaptic plasticity caused by prenatal ethanol exposure. Neuroscience Letters. 551: 7-11. PMID 23872044 DOI: 10.1016/j.neulet.2013.05.051 |
0.84 |
|
2013 |
Patten AR, Brocardo PS, Christie BR. Omega-3 supplementation can restore glutathione levels and prevent oxidative damage caused by prenatal ethanol exposure. The Journal of Nutritional Biochemistry. 24: 760-9. PMID 22841392 DOI: 10.1016/j.jnutbio.2012.04.003 |
0.799 |
|
2012 |
Brocardo PS, Boehme F, Patten A, Cox A, Gil-Mohapel J, Christie BR. Anxiety- and depression-like behaviors are accompanied by an increase in oxidative stress in a rat model of fetal alcohol spectrum disorders: Protective effects of voluntary physical exercise. Neuropharmacology. 62: 1607-18. PMID 22019722 DOI: 10.1016/J.Neuropharm.2011.10.006 |
0.801 |
|
2011 |
Boehme F, Gil-Mohapel J, Cox A, Patten A, Giles E, Brocardo PS, Christie BR. Voluntary exercise induces adult hippocampal neurogenesis and BDNF expression in a rodent model of fetal alcohol spectrum disorders. The European Journal of Neuroscience. 33: 1799-811. PMID 21535455 DOI: 10.1111/J.1460-9568.2011.07676.X |
0.817 |
|
2011 |
Gil-Mohapel J, Boehme F, Patten A, Cox A, Kainer L, Giles E, Brocardo PS, Christie BR. Altered adult hippocampal neuronal maturation in a rat model of fetal alcohol syndrome. Brain Research. 1384: 29-41. PMID 21303667 DOI: 10.1016/J.Brainres.2011.01.116 |
0.812 |
|
Low-probability matches (unlikely to be authored by this person) |
2010 |
Goulton CS, Patten AR, Kerr JR, Kerr DS. Pharmacological Preconditioning with GYKI 52466: A Prophylactic Approach to Neuroprotection. Frontiers in Neuroscience. 4. PMID 20953290 DOI: 10.3389/fnins.2010.00054 |
0.16 |
|
2014 |
Baulac M, Patten A, Giorgi L. Long-term safety and efficacy of zonisamide versus carbamazepine monotherapy for treatment of partial seizures in adults with newly diagnosed epilepsy: Results of a phase III, randomized, double-blind study Epilepsia. 55: 1534-1543. PMID 25109239 DOI: 10.1111/epi.12749 |
0.118 |
|
2012 |
Baulac M, Brodie MJ, Patten A, Segieth J, Giorgi L. Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: A phase 3, randomised, double-blind, non-inferiority trial The Lancet Neurology. 11: 579-588. PMID 22683226 DOI: 10.1016/S1474-4422(12)70105-9 |
0.087 |
|
2022 |
Segal E, Wheless J, Moretz K, Penovich P, Patten A, Malhotra M. Perampanel in real-world clinical care of adolescent and adult patients with epilepsy: Results from the retrospective Phase IV PROVE Study. Seizure. 98: 87-94. PMID 35453064 DOI: 10.1016/j.seizure.2022.02.011 |
0.085 |
|
2014 |
Cross JH, Auvin S, Patten A, Giorgi L. Safety and tolerability of zonisamide in paediatric patients with epilepsy European Journal of Paediatric Neurology. 18: 747-758. PMID 25128350 DOI: 10.1016/j.ejpn.2014.07.005 |
0.084 |
|
2021 |
Morgan KA, Paton S, Patten A, Tucker S, Walker K. Community-based exercise goals of persons with spinal cord injury: Interpreted using the International Classification of Functioning, Disability, and Health. The Journal of Spinal Cord Medicine. 1-10. PMID 34698620 DOI: 10.1080/10790268.2021.1970896 |
0.079 |
|
2022 |
French JA, Wechsler RT, Trinka E, Brandt C, O'Brien TJ, Patten A, Salah A, Malhotra M. Long-term open-label perampanel: Generalized tonic-clonic seizures in idiopathic generalized epilepsy. Epilepsia Open. PMID 35445567 DOI: 10.1002/epi4.12602 |
0.074 |
|
2020 |
Rektor I, Krauss GL, Inoue Y, Kaneko S, Williams B, Patten A, Malhotra M, Laurenza A, Wechsler RT. Assessment of the long-term efficacy and safety of adjunctive perampanel in tonic-clonic seizures: Analysis of four open-label extension studies. Epilepsia. PMID 32645213 DOI: 10.1111/epi.16573 |
0.072 |
|
2022 |
Piña-Garza JE, Villanueva V, Rosenfeld W, Yoshinaga H, Patten A, Malhotra M. Assessment of the long-term efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: Post hoc analysis of open-label extension studies. Epilepsy & Behavior : E&B. 135: 108901. PMID 36122531 DOI: 10.1016/j.yebeh.2022.108901 |
0.072 |
|
2023 |
Nishida T, Lee SK, Inoue Y, Saeki K, Ishikawa K, Malhotra M, Patten A, Kaneko S. Long-Term Efficacy and Safety of Adjunctive Perampanel in Patients From the Asia-Pacific Region With Refractory Focal-Onset Seizures in Study 335 Open-Label Extension. Epilepsia Open. PMID 37867420 DOI: 10.1002/epi4.12849 |
0.069 |
|
2017 |
Chung S, Williams B, Dobrinsky C, Patten A, Yang H, Laurenza A. Perampanel with concomitant levetiracetam and topiramate: Post hoc analysis of adverse events related to hostility and aggression. Epilepsy & Behavior : E&B. 75: 79-85. PMID 28830031 DOI: 10.1016/j.yebeh.2017.06.038 |
0.069 |
|
2021 |
Maguire M, Ben-Menachem E, Patten A, Malhotra M, Ngo LY. A post-approval observational study to evaluate the safety and tolerability of perampanel as an add-on therapy in adolescent, adult, and elderly patients with epilepsy. Epilepsy & Behavior : E&B. 126: 108483. PMID 34953337 DOI: 10.1016/j.yebeh.2021.108483 |
0.066 |
|
2021 |
Kanner AM, Patten A, Ettinger AB, Helmstaedter C, Meador KJ, Malhotra M. Does a psychiatric history play a role in the development of psychiatric adverse events to perampanel… and to placebo? Epilepsy & Behavior : E&B. 125: 108380. PMID 34735963 DOI: 10.1016/j.yebeh.2021.108380 |
0.065 |
|
2018 |
Kwan P, Mintzer S, Laurenza A, Patten A, Cartwright K. Evaluation of perampanel as monotherapy for focal seizures: Experience from open-label extension studies. Epilepsy & Behavior Case Reports. 9: 1-5. PMID 29707476 DOI: 10.1016/j.ebcr.2017.11.001 |
0.058 |
|
2015 |
Yang H, Laurenza A, Williams B, Patten A, Hussein Z, Ferry J. Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials. Epilepsy Research. 114: 122-30. PMID 26088895 DOI: 10.1016/j.eplepsyres.2015.04.010 |
0.057 |
|
2022 |
Resnick T, Patten A, Ngo LY, Malhotra M. Sustained seizure freedom with adjunctive perampanel in patients with convulsive seizures: Post hoc analysis of open-label extension studies 307 and 332. Epilepsy & Behavior : E&B. 128: 108528. PMID 35078116 DOI: 10.1016/j.yebeh.2021.108528 |
0.055 |
|
2021 |
Krauss GL, Ben-Menachem E, Wechsler RT, Patten A, Williams B, Laurenza A, Malhotra M. A multivariable prediction model of a major treatment response for focal-onset seizures: A post-hoc analysis of Phase III trials of perampanel. Epilepsy Research. 174: 106649. PMID 34022524 DOI: 10.1016/j.eplepsyres.2021.106649 |
0.054 |
|
2020 |
Brandt C, Wechsler RT, O'Brien TJ, Patten A, Malhotra M, Ngo LY, Steinhoff BJ. Adjunctive perampanel and myoclonic and absence seizures: Post hoc analysis of data from study 332 in patients with idiopathic generalized epilepsy. Seizure. 80: 115-123. PMID 32563171 DOI: 10.1016/J.Seizure.2020.06.011 |
0.053 |
|
2012 |
Rascol O, Barone P, Behari M, Emre M, Giladi N, Olanow CW, Ruzicka E, Bibbiani F, Squillacote D, Patten A, Tolosa E. Perampanel in Parkinson disease fluctuations: a double-blind randomized trial with placebo and entacapone. Clinical Neuropharmacology. 35: 15-20. PMID 22222634 DOI: 10.1097/Wnf.0B013E318241520B |
0.053 |
|
2020 |
Trinka E, Tsong W, Toupin S, Patten A, Wilson K, Isojarvi J, James D. A systematic review and indirect treatment comparison of perampanel versus brivaracetam as adjunctive therapy in patients with focal-onset seizures with or without secondary generalization. Epilepsy Research. 166: 106403. PMID 32673969 DOI: 10.1016/j.eplepsyres.2020.106403 |
0.051 |
|
2020 |
Piña-Garza JE, Rosenfeld W, Saeki K, Villanueva V, Yoshinaga H, Patten A, Williams B, Malhotra M. Efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: Post hoc analysis of six randomized studies. Epilepsy & Behavior : E&B. 104: 106876. PMID 31954998 DOI: 10.1016/j.yebeh.2019.106876 |
0.05 |
|
2021 |
Husni RE, Ngo LY, Senokuchi H, Patten A, Hiramatsu H, Watanabe K, Yamamoto T. Experience of perampanel monotherapy beyond initial titration to achieve seizure freedom in patients with focal-onset seizures with newly diagnosed or currently untreated recurrent epilepsy: a post hoc analysis of the open-label Study 342 (FREEDOM). Epilepsia Open. PMID 34657389 DOI: 10.1002/epi4.12551 |
0.048 |
|
2018 |
Krauss GL, Perucca E, Kwan P, Ben-Menachem E, Wang XF, Shih JJ, Patten A, Yang H, Williams B, Laurenza A. Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307. Epilepsia. PMID 29574701 DOI: 10.1111/epi.14044 |
0.047 |
|
2020 |
Fogarasi A, Flamini R, Milh M, Phillips S, Yoshitomi S, Patten A, Takase T, Laurenza A, Ngo LY. Open-label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (4 to <12 years) with inadequately controlled focal seizures or generalized tonic-clonic seizures. Epilepsia. 61: 125-137. PMID 31912493 DOI: 10.1111/epi.16413 |
0.046 |
|
2023 |
Omatsu H, Watanabe T, Kira R, Ishiba K, Patten A, Takase T, Ngo LY. Open-label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (aged 4 to <12 years) with inadequately controlled focal-onset seizures: Japanese subgroup analysis. Seizure. 110: 109-116. PMID 37336055 DOI: 10.1016/j.seizure.2023.06.004 |
0.045 |
|
2022 |
Kerr WT, Brandt C, Ngo LY, Patten A, Cheng JY, Kramer L, French JA. Time to exceed pre-randomization monthly seizure count for perampanel in participants with primary generalized tonic-clonic seizures: a potential clinical endpoint. Epilepsia. PMID 36106379 DOI: 10.1111/epi.17411 |
0.044 |
|
2022 |
Segal E, Moretz K, Wheless J, Penovich P, Lancman M, Patten A, Malhotra M. PROVE-Phase IV Study of Perampanel in Real-World Clinical Care of Patients with Epilepsy: Interim Analysis in Pediatric Patients. Journal of Child Neurology. 8830738211047665. PMID 34994582 DOI: 10.1177/08830738211047665 |
0.041 |
|
2020 |
Weiping L, Dong Z, Zhen H, Patten A, Dash A, Malhotra M. Efficacy, safety, and tolerability of adjunctive perampanel in patients from China with focal seizures or generalized tonic-clonic seizures: Post hoc analysis of phase III double-blind and open-label extension studies. Cns Neuroscience & Therapeutics. PMID 33340263 DOI: 10.1111/cns.13458 |
0.041 |
|
2021 |
Mehndiratta MM, Gulhane M, Jabeen SA, Patten A, Dash A, Malhotra M. Efficacy and safety of adjunctive perampanel in patients with focal seizures or generalized tonic-clonic seizures: Post hoc analysis of Phase II and Phase III double-blind and open-label extension studies in India. Epilepsia Open. 6: 90-101. PMID 33681652 DOI: 10.1002/epi4.12448 |
0.038 |
|
2017 |
Gil-Nagel A, Burd S, Toledo M, Sander JW, Lebedeva A, Patten A, Laurenza A. A retrospective, multicentre study of perampanel given as monotherapy in routine clinical care in people with epilepsy. Seizure. 54: 61-66. PMID 29288911 DOI: 10.1016/j.seizure.2017.10.015 |
0.037 |
|
2016 |
Leppik IE, Yang H, Williams B, Zhou S, Fain R, Patten A, Bibbiani F, Laurenza A. Analysis of falls in patients with epilepsy enrolled in the perampanel phase III randomized double-blind studies. Epilepsia. PMID 27869305 DOI: 10.1111/epi.13600 |
0.034 |
|
2020 |
Steinhoff BJ, Patten A, Williams B, Malhotra M. Efficacy and safety of adjunctive perampanel 4 mg/d for the treatment of focal seizures: A pooled post hoc analysis of four randomized, double-blind, phase III studies. Epilepsia. PMID 31944276 DOI: 10.1111/epi.16428 |
0.034 |
|
2015 |
French JA, Krauss GL, Wechsler RT, Wang XF, DiVentura B, Brandt C, Trinka E, O'Brien TJ, Laurenza A, Patten A, Bibbiani F. Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy: A randomized trial. Neurology. PMID 26296511 DOI: 10.1212/Wnl.0000000000001930 |
0.028 |
|
2021 |
Wechsler RT, Wheless J, Zafar M, Huesmann GR, Lancman M, Segal E, Chez M, Aboumatar S, Patten A, Salah A, Malhotra M. PROVE: retrospective, non-interventional, Phase IV study of perampanel in real-world clinical care of patients with epilepsy. Epilepsia Open. PMID 34942053 DOI: 10.1002/epi4.12575 |
0.019 |
|
2021 |
Wheless J, Wechsler RT, Lancman M, Aboumatar S, Patten A, Malhotra M. Perampanel in real-world clinical care of patients with epilepsy: Interim analysis of a phase IV study. Epilepsia Open. 6: 79-89. PMID 33681651 DOI: 10.1002/epi4.12445 |
0.017 |
|
Hide low-probability matches. |